DNAPrint to Present at Upcoming Conferences
SARASOTA, Fla., Oct. 16 /PRNewswire/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) announced today that it has been invited to present at two of America's largest genomics conferences.
On October 27 2000, DNAPrint will present at TIGR's Genome Sequencing and Analysis Conference (GSAC), to be held at the San Diego Convention Center in San Diego, CA. The GSAC meeting is chaired by J. Craig Venter, Ph.D., Celera Genomics (NYSE: CRA), Dennis Hochstrasser, MD, of Geneva University Hospital and Yusuke Nakamura, MD, Ph.D. of the University of Tokyo, and is perhaps the world's most recognized and comprehensive genomics conference.
In March of 2002, Dr. Frudakis will present at the BioIT World Conference and Expo at the World Trade Center in Boston MA. BioIT is organized by IDG of Framingham Massachusetts, and is expected to serve as the world's primary conference for computational and analytical genomics. Dr. Frudakis sits on the Advisory Board for the Bio IT World Expo and Conference.
At both conferences, Dr. Frudakis will present results from the company's personalized medicine research and product development efforts.
About DNAPrint genomics, Inc.:
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol -- DNAP. For more information about the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
DNAPrint genomics, Inc., Sarasota
For scientific inquiries please contact:
Dr. Tony Frudakis, 941/366-3400
All other inquiries please contact:
Tim Wilkins, 941/341-0136 |
